crossing96/oncoscreening huggingface dataset:
Enhancement of drug delivery through fibroblast activation protein-targeted near-infrared photoimmunotherapy.	The tumor microenvironment plays a key role in cancer progression and therapy resistance, with cancer-associated fibroblasts (CAFs) contributing to desmoplasia, extracellular matrix (ECM) remodeling, and elevated interstitial fluid pressure, all of which hinder drug delivery. We investigated fibroblast activation protein-targeted (FAP-targeted) near-infrared photoimmunotherapy (NIR-PIT) as a strategy to improve drug penetration in CAF-rich tumors. In clinical esophageal cancer samples, FAP expression strongly correlated with increased collagen I, hyaluronic acid, and microvascular collapse. CAF-rich 3D spheroids demonstrated elevated ECM deposition and significantly impaired drug uptake compared with CAF-poor models. FAP-targeted NIR-PIT selectively reduced CAFs, reduced ECM components, and restored drug permeability. In vivo, FAP-targeted NIR-PIT enhanced the accumulation of panitumumab and Abraxane in CAF-rich tumors and improved antitumor efficacy when combined with chemotherapy. These findings highlight FAP-targeted NIR-PIT as a promising therapeutic approach to remodel the tumor stroma and overcome drug resistance in desmoplastic solid tumors.	esophagus
Surgical treatment in synchronous oesophageal cancers - A systematic review on survival outcomes.	OBJECTIVE: It is crucial to consider that other primary cancers may co-occur with synchronous oesophageal cancers when evaluating and deciding on treatment. This research aimed to assess available information on the viability and safety of synchronous resection of oesophageal carcinomas. METHODS: A systematic literature search was conducted on PubMed, Scopus, Cochrane Central Register of Controlled Trials, and EMBASE to identify 34 peer-reviewed articles up to 2025. It included randomised controlled trials (RCTs), controlled clinical trials, observational studies, cohort studies, and case-control studies with adult patients (≥18 years) undergoing surgery. RESULTS: Studies on the surgical management of oesophageal cancer metastasis revealed that the median overall survival within 1-3 years ranged from 21.% % to 32 %. In one study, the 5-year median survival was 38.8 % in TTE and 23 % in esophagectomy plus gastrectomy. Regarding data on case series, concomitant stomach and oesophageal neoplasms were present in 89 patients (76 % of the overall group). Seventy-five patients had adenocarcinomas, whereas the remaining 10 patients had gastrointestinal stromal tumours (GISTs). Eighty-seven patients had a transthoracic echocardiogram (TTE), one patient had a transhiatal esophagectomy (THE), and one patient had a thoracoabdominal approach. The remaining 59 patients had gastrectomies that left some stomach tissue intact. In 93 % of the patients, the second primary tumour could be diagnosed prior to surgery. CONCLUSION: Concurrent resection of oesophageal and other primary solid organ cancers is safe, technically possible, and linked to acceptable perioperative death rates on an individual basis.	esophagus
Prognostic implications of microRNA-107 in esophageal cancer: a retrospective cohort study.	BACKGROUND: Esophageal squamous cell carcinoma (ESCC) imposes a heavy disease burden in China, accounting for over 50% of global cases and approximately 301,000 annual deaths. Current prognostic markers inadequately predict recurrence in early-stage patients. This study investigates microRNA-107 (miR-107) as a novel prognostic biomarker for ESCC. METHODS: Tumor tissues (n = 66) and adjacent normal tissues (n = 28) were collected from ESCC patients undergoing radical surgery (2010-2012). miR-107 expression was quantified via reverse transcription quantitative polymerase chain reaction (RT-qPCR) (normalized to U6 snRNA). Clinicopathological correlations and survival outcomes were analyzed using χ (2) tests, Kaplan-Meier/log-rank tests, and Cox regression. Comparative analysis of miR-107 levels was performed in human esophageal squamous cell carcinoma line 109 (EC109) cancer cells versus human esophageal epithelial cell (HEEC) normal epithelial cells. RESULTS: miR-107 expression was significantly lower in esophageal cancer tissues (0.801 ± 0.737) compared to adjacent non-cancerous tissues (1.390 ± 1.346), p = 0.006. Low miR-107 expression (cutoff = median) correlated with advanced tumor, node, metastasis stage (TNM stage) (I vs. V: 100% vs. 21.4%, P < 0.001), lymph node metastasis (73.1% vs. 35%, P < 0.001), and larger tumor size (70% vs. 33.3%, P < 0.001). Patients with low miR-107 had shorter median overall survival (10 vs. 59 months; Hazard Ratio (HR) = 0.475, 95% Confidence Interval (CI) [0.247-0.915]; P < 0.001). Multivariate Cox analysis confirmed miR-107 as an independent prognostic factor alongside TNM stage (HR = 3.586, 95% CI [2.253-5.708]; P < 0.001). Consistently, EC109 cells exhibited 59% lower miR-107 levels than HEEC (P = 0.029). CONCLUSIONS: miR-107 downregulation is a robust predictor of aggressive ESCC phenotypes and poor survival. It holds promise as a clinical biomarker for risk stratification and personalized therapy. Future studies should validate these findings in multicenter cohorts and elucidate miR-107's functional mechanisms.	esophagus
[da Vinci Single-port Esophagectomy via the Subcostal Approach].	The introduction of the da Vinci SP system has led to the classification of surgical robotic platforms into multiple-port and single-port systems. Esophagectomy for esophageal cancer can now be performed through various approaches, including transthoracic, transcervical, transhiatal, and subcostal routes. Future studies are warranted to determine which robotic system is most suitable for each approach and provides optimal short- and long-term outcomes.	esophagus
Integrated bioinformatics analysis of differences between EAC and ESCC.	BACKGROUND: As the major subtypes of esophageal cancer (EC), esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) exhibit distinct etiological mechanism, epidemiology, tumor biology, and prognoses. We performed bioinformatics analysis on specific genes related to pathological subtypes to identify potential biomarkers and therapeutic targets. METHODS: Differentially expressed genes (DEGs) between tumor and normal tissues were identified from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Weighted gene co-expression network analysis (WGCNA) was subsequently employed to screen genes associated with pathological subtypes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations, along with gene set enrichment analysis (GSEA), were performed to elucidate the biological roles of these DEGs. A protein‒protein interaction (PPI) network was constructed to explore the hub genes. Furthermore, the prognostic genes were identified via LASSO Cox regression. The differences between EAC and ESCC in terms of immune cell infiltration, somatic mutations, copy number variations (CNVs), and drug sensitivity were subsequently analyzed. RESULTS: A total of 131 genes were identified as EAC-specific DEGs, whereas 49 genes were recognized as ESCC-specific DEGs. Enrichment analysis revealed significant enrichment of the extracellular matrix (ECM)-related pathway, along with the cell cycle, epithelial‒mesenchymal transition (EMT), and hypoxia signaling pathways, in ESCC. Conversely, EAC was associated with alterations in tumor metabolism, particularly glycolysis and gluconeogenesis. For EAC, a prognostic risk model was constructed, including RHOV, SYTL1, MT1X, PRRG4, KCNK5, and CCL20, which demonstrated robust predictive capabilities for patient outcomes. In ESCC, TUSC3 was identified as a prognostic biomarker and was validated in tissue samples. Furthermore, an in-depth analysis revealed distinct patterns in immune cell infiltration, somatic mutations, CNVs, and drug sensitivity between EAC and ESCC. CONCLUSIONS: In this study, pathologically specific genes were identified in EAC and ESCC. These findings might provide valuable insights into the molecular mechanisms and potential therapeutic targets for these two distinct subtypes.	esophagus
Automated Esophageal Cancer Staging From Free-Text Radiology Reports: Large Language Model Evaluation Study.	BACKGROUND: Accurate staging of esophageal cancer is crucial for determining prognosis and guiding treatment strategies, but manual interpretation of radiology reports by clinicians is prone to variability and limited accuracy, resulting in reduced staging accuracy. Recent advances in large language models (LLMs) have shown promise in medical applications, but their utility in esophageal cancer staging remains underexplored. OBJECTIVE: This study aims to compare the performance of 3 locally deployed LLMs (INF-72B, Qwen2.5-72B, and LLaMA3.1-70B) and clinicians in preoperative esophageal cancer staging using free-text radiology reports. METHODS: This retrospective study included 200 patients from Shanghai Chest Hospital who underwent esophageal cancer surgery from May to December 2024. The dataset consisted of 1134 Chinese free-text radiology reports. The reference standard was derived from postoperative pathological staging. A total of 3 LLMs determined tumor classification (T1-T4), node classification (N0-N3), and overall staging (I-IV) using 3 prompting strategies (zero-shot, chain-of-thought, and a proposed interpretable reasoning [IR] method). The McNemar test and Pearson chi-square test were used for comparisons. RESULTS: INF-72B+IR achieved a superior overall staging accuracy of 61.5% and an F1-score of 0.60, substantially higher than the clinicians' accuracy of 39.5% and F1-score of 0.39 (all P<.001). Qwen2.5-72B+IR also demonstrated an advantage, achieving an overall staging accuracy of 46% and an F1-score of 0.51, which was better than the clinicians' performance (P<.001). LLaMA3.1-70B showed no statistically significant difference in overall staging performance compared to clinicians (all P>0.5). CONCLUSIONS: This study demonstrates that LLMs, particularly when guided by the proposed IR strategy, can accurately and reliably perform esophageal cancer staging from free-text radiology reports. This approach not only provides high-performance predictions but also offers a transparent and verifiable reasoning process, highlighting its potential as a valuable decision-support tool to augment human expertise in complex clinical diagnostic tasks.	esophagus
PICC Maintenance Challenges Among Esophageal Cancer Patients: A Qualitative Study.	BACKGROUND: Esophageal cancer is a prevalent malignancy worldwide, often accompanied by dysphagia and malnutrition that necessitate long-term intravenous nutritional support. Peripherally Inserted Central Catheters (PICCs) have become a standard nursing practice to facilitate chemotherapy and parenteral nutrition in these patients. However, maintaining PICCs poses significant challenges that can affect patient adherence and outcomes. OBJECTIVE: This study aims to explore the experiences and needs of esophageal cancer patients regarding PICC maintenance after hospital discharge, with the goal of providing evidence to optimize nursing care services. METHODS: A qualitative study was conducted involving semi-structured interviews with 15 esophageal cancer patients receiving PICC care at a specialized oncology hospital in Beijing from October 2024 to January 2025. Descriptive phenomenological methods were used to analyze the data following Colaizzi's seven-step approach. RESULTS: Patient experiences clustered into four main themes: (1) Survival under the combined pressures of nutritional needs and chemotherapy; (2) Maintenance challenges influenced by anatomical and treatment-related factors; (3) Adherence difficulties due to symptoms and frequent hospital visits; (4) Emotional responses to dramatic physical changes and distressing symptoms. CONCLUSION: Esophageal cancer patients face complex, multifaceted needs during PICC maintenance, encompassing practical care, informational support, and psychological assistance. To improve patient adaptation and quality of life, future nursing practices should focus on enhancing care techniques, developing accessible support tools, and strengthening health education strategies.	esophagus
Predictive modeling of flavonoid efficacy against esophageal carcinoma: a comprehensive approach.	Esophageal carcinoma poses a significant health challenge, particularly due to its notably high prevalence in East Asia, which underscores the urgent need for innovative treatment strategies. Natural flavonoids are polyphenolic compounds with significant potential to interact with cancer cell pathways; however, their therapeutic application remains constrained by the lack of comprehensive data and consistent experimental evidence. The current study aims to present a comprehensive framework for evaluating the anticancer potential of natural flavonoids, including seven flavones-luteolin, apigenin, chrysin, acacetin, cirsiliol, baicalein and eupatilin-and six flavonols-kaempferol, quercetin, galangin, myricetin, casticin, and gossyptin-against human esophageal carcinoma cells. Extensive experimental data from twenty-two research studies focusing on natural flavonoids and esophageal carcinoma cells were extracted based on specific inclusion criteria that emphasized dose, time, and cell viability. Seven machine learning models-K-Nearest Neighbors, Support Vector Machine, Logistic Regression, Decision Tree (DT), Random Forest, AdaBoost and XGBoost-were employed to predict the optimal dose and time required for flavonoids to achieve 50% cancer cell viability. Hyperparameters were fine-tuned for each algorithm, followed by 5-fold cross-validation on the train dataset to identify the most accurate predictive model. The performance of each algorithm was validated through rigorous hyperparameter optimization and validation on an independent test dataset. The DT model was identified as the most accurate predictor, leading to the development of a simplified model with low complexity that achieved an accuracy of 87.38%. This reliable model enables prediction of effective dosing parameters across diverse esophageal carcinoma cell lines. In conclusion, present study offers a robust yet accessible predictive tool for optimizing treatment strategies against esophageal carcinoma. By combining machine learning with natural compound research, this work exemplifies a transformative approach in oncology, accelerating the development of effective cancer therapies.	esophagus
Discovery of Novel PI3K/BRD4 Dual Inhibitors for Esophageal Cancer: Rational Design, Optimization, and Senescence-Inducing Mechanisms.	The discovery of novel targeted therapies for esophageal cancer represents an urgent clinical need. Herein, we reported the rational design and synthesis of novel PI3K/BRD4 dual inhibitors for the treatment of esophageal cancer. Systematic structure-activity relationship studies identified compound 23 as a potent dual-targeting inhibitor that effectively suppresses PI3K and BRD4 signaling. In vitro, 23 inhibited proliferation, migration, invasion, and colony formation of esophageal cancer cells. In vivo, 23 demonstrated anticancer efficacy comparable to that of the BKM120/JQ1 combination treatment in a KYSE450 xenograft mouse model. Mechanistically, 23 induces cellular senescence via the AMPK-p27 pathway. Significantly, the senolytic agent ABT737 enhanced the efficacy of compound 23 through the selective clearance of senescent cancer cells. Collectively, this work establishes 23 as a promising PI3K/BRD4 dual-targeting lead and supports senescence induction combined with senolytics as a novel strategy for esophageal cancer treatment.	esophagus
LINC01605 Suppresses Esophageal Squamous Carcinogenesis by Regulating Squamous Cell Differentiation, Proliferation, and Migration.	BACKGROUND: Esophageal squamous cell carcinoma (ESCC) develops through a multistage process in which normal epithelium transitions into intraepithelial neoplasia and ultimately into invasive carcinoma. Elucidating the molecular changes and functional roles of key genes during this progression is critical for understanding the mechanisms underlying this malignant transformation. METHODS: Transcriptomic profiles of 12 normal esophageal tissues, 5 intraepithelial neoplasia tissues, and 7 ESCC tissues were analyzed via microarray. Stage-specific transcriptomic changes were systematically compared to delineate the phenotypic evolution that occurs during carcinogenesis, with a particular focus on identifying pivotal genes that regulate the precancerous-to-malignant transition. The candidate gene LINC01605 was further examined via the following approaches: (1) bioinformatics-based characterization of its tumor-associated functions using Genotype-Tissue Expression Project (GTEx) normal tissue and The Cancer Genome Atlas Program (TCGA) ESCC transcriptome; (2) functional validation in ESCC cell lines in which the gene was silenced or overexpressed in vitro; and (3) mechanistic exploration of RNA-binding partners via streptavidin bead-based RNA pull-down assays. RESULTS: Multistage transcriptomic analysis revealed the progressive acquisition of cancer hallmarks during ESCC development. The transition from precancerous lesions to invasive carcinoma was characterized by epithelial dedifferentiation, extracellular matrix remodeling, and angiogenesis. LINC01605, which is a long noncoding RNA (lncRNA), was downregulated during this transition. GTEx revealed that LINC01605 was specifically expressed in the squamous epithelium of the esophagus and that its expression was negatively correlated with histological grade in the TCGA-ESCC dataset. Samples with high LINC01605 expression and those with low LINC01605 expression in the TCGA dataset exhibited significant functional differences in epithelial cell differentiation, proliferation, and migration, as well as in the extracellular matrix. Knocking down LINC01605 increased proliferation and migration in both the normal immortalized esophageal epithelial cell line NE3 and the ESCC cell line KYSE180. Conversely, the overexpression of LINC01605 isoforms suppressed these malignant phenotypes. RNA pull-down revealed potential interactions between LINC01605 and aurora kinase B (AURKB), which are components of the chromosomal passenger complex (CPC), suggesting its involvement in regulating the cell cycle. CONCLUSION: LINC01605 functions as a tumor suppressor in ESCC by maintaining squamous cell differentiation and inhibiting proliferation and migration. LINC01605 downregulation facilitates malignant transformation during esophageal carcinogenesis.	esophagus
DENR reduces cisplatin sensitivity in esophageal squamous cell carcinoma via ATF4-Mediated ferroptosis inhibition.	BACKGROUND: Cisplatin (DDP)-based chemotherapy is a cornerstone in the treatment of esophageal squamous cell carcinoma (ESCC), yet resistance to DDP remains a major clinical obstacle. Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in tumor sensitivity to chemotherapy. However, the molecular mechanisms governing ferroptosis in ESCC remain incompletely understood. OBJECTIVE: This study aimed to investigate the role of density-regulated re-initiation and release factor (DENR) in regulating cisplatin sensitivity in ESCC, with a particular focus on its involvement in ferroptosis through activating transcription factor 4 (ATF4). RESULTS: DENR was significantly upregulated in ESCC and associated with poor prognosis. DENR overexpression reduced the sensitivity of ESCC cells to DDP and suppressed ferroptosis, as evidenced by decreased ROS accumulation, Fe(2+) levels, and ferroptosis marker expression. Conversely, DENR knockdown enhanced ferroptosis and DDP-induced cytotoxicity. Mechanistically, DENR promoted ATF4 expression, and silencing ATF4 partially reversed the ferroptosis-inhibitory and DDP resistance effects mediated by DENR. In vivo, DENR overexpression enhanced tumor growth and diminished DDP efficacy, which was mitigated by ATF4 knockdown. CONCLUSION: DENR promotes cisplatin resistance in ESCC by inhibiting ferroptosis through an ATF4-dependent mechanism. Targeting the DENR/ATF4 axis may represent a promising strategy to overcome chemoresistance in ESCC.	esophagus
Expandable versus inflatable mediastinoscopic combined with laparoscopic for radical esophagectomy.	"BACKGROUND: A few medical centers have used the ""inflatable mediastinoscope"" technology in radical esophagectomy for esophageal cancer, and its safety and short-term efficacy have been limitedly verified. However, this technology has some defects. Therefore, we developed a new method for radical resection of esophageal cancer: the expanded mediastinoscopic combined with laparoscopic radical esophagectomy (EMLE). METHODS: From June 2019 to June 2022, we successfully performed 176 cases of radical resection of esophageal cancer using the new EMLE technique and recorded the baseline and perioperative patient data. We also retrieved four published clinical studies on the inflatable mediastinoscopic combined with laparoscopic radical esophagectomy (IMLE) and compared the perioperative safety differences between EMLE and IMLE. RESULTS: The EMLE group comprised 176 patients, whereas the IMLE group had 173 patients. Compared to IMLE, patients undergoing EMLE showed almost no differences in baseline characteristics but demonstrated significant advantages in terms of operative time (329.71 vs. 168.84 min) and blood loss (167.84 vs. 94.87 mL) (P < 0.001). The incidence of postoperative complications was significantly lower in the EMLE group compared to the IMLE group (P < 0.001). Specifically, the incidence of postoperative recurrent laryngeal nerve palsy was significantly lower in the EMLE group than in the IMLE group (P < 0.001). No significant differences existed in the days of the postoperative hospital stay and number of resected lymph nodes. CONCLUSION: EMLE has no disadvantages compared with IMLE. It is a radical resection of esophageal cancer with more advantages in surgical operation and blood loss control and is also worth promoting."	esophagus
Prognostic value of nutritional risk index in esophageal cancer: A protocol for systematic review and meta-analysis.	BACKGROUND: The nutritional risk index (NRI) and its modified version, the geriatric nutritional risk index (GNRI), are simple formula-based tools reflecting nutritional and inflammatory status. While several studies have investigated their prognostic value in esophageal cancer (EC), results remain inconsistent, and no prior meta-analysis has directly compared NRI and GNRI in this context. Therefore, this meta-analysis was conducted to thoroughly assess the prognostic significance of NRI/GNRI in EC. METHODS: Possible studies were obtained from Embase, Web of Science, PubMed, and Cochrane Library from their inception to November 2024. A relative ratio (RR) and a hazard ratio (HR) were extracted and pooled to analyze the correlation between the prognosis of EC and NRI/GNRI. RESULTS: The final meta-analysis included 10 studies, with 2600 patients. As displayed in the pooled results, high NRI/GNRI predicted superior overall survival (HR = 1.78, 95% confidence interval [CI]: 1.53-2.07, P < .01) and distant metastasis-free survival/progression-free survival/recurrence-free survival (HR = 1.95, 95% CI: 1.52-2.51, P < .01). The association was presented between low NRI/GNRI and more lymph node metastasis (RR = 1.18, 95% CI: 1.01-1.38, P = .040), deeper tumor invasion (RR = 1.18, 95% CI: 1.01-1.38, P = .040), as well as advanced tumor stage (RR = 1.32, 95% CI: 1.10-1.58, P = .003). CONCLUSION: Both NRI and GNRI are independent prognostic factors in EC. Incorporating nutritional risk screening into routine clinical practice may support early intervention and improve treatment outcomes, particularly in surgical patients.	esophagus